Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of <scp>EBMT</scp>-Reference-Cited by-同舟云学术

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT

Published:2024-02-22 Issue:5 Volume:99 Page:993-996
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Polverelli Nicola¹^ORCID,Bonneville Edouard F.²³^ORCID,de Wreede Liesbeth C.²,Koster Linda³,Kröger Nicolaus Martin⁴,Schroeder Thomas⁵,Peffault de Latour Régis⁶^ORCID,Passweg Jakob⁷,Sockel Katja⁸,Broers Annoek E. C.⁹,Clark Andrew¹⁰,Dreger Peter¹¹,Blaise Didier¹²,Yakoub‐Agha Ibrahim¹³,Petersen Soeren Lykke¹⁴,Finke Jürgen¹⁵,Chevallier Patrice¹⁶^ORCID,Helbig Grzegorz¹⁷,Rabitsch Werner¹⁸,Sammassimo Simona¹⁹,Arcaini Luca¹²⁰^ORCID,Russo Domenico²¹,Drozd‐Sokolowska Joanna²²,Raj Kavita²³,Robin Marie⁶^ORCID,Battipaglia Giorgia²⁴,Czerw Tomasz²⁵^ORCID,Hernández‐Boluda Juan Carlos²⁶^ORCID,McLornan Donal P.²³

Affiliation:

1. Unit of Bone Marrow Transplantation, Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy

2. Department of Biomedical Data Sciences Leiden University Medical Center Leiden The Netherlands

3. EBMT Leiden Study Unit Leiden The Netherlands

4. Department of Stem Cell Transplantation University Medical Center Hamburg‐Eppendorf Hamburg Germany

5. Department of Hematology and Stem Cell Transplantation West German Cancer Center, University Hospital of Essen Essen Germany

6. BMT Unit Saint‐Louis Hospital Paris France

7. Hematology Division University Hospital Basel Switzerland

8. Universitaetsklinikum Dresden Dresden Germany

9. Erasmus MC Cancer Institute Rotterdam The Netherlands

10. Beatson West of Scotland Cancer Centre Glasgow United Kingdom

11. University of Heidelberg Heidelberg Germany

12. Programme de Transplantation & Therapie Cellulaire Marseille France

13. CHU de Lille Lille France

14. Bone Marrow Transplant Unit, Department of Hematology Copenhagen University Hospital Copenhagen Denmark

15. Department of Medicine Medical Center‐University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany

16. CHU Nantes Nantes France

17. Department of Hematology and Bone Marrow Transplantation School of Medicine in Katowice, Medical University of Silesia Katowice Poland

18. BMT Unit, Internal Medicine I Medical University of Vienna Vienna Austria

19. Onco‐Hematology Division IEO, European Institute of Oncology IRCCS Milan Italy

20. Department of Molecular Medicine University of Pavia Pavia Italy

21. Unit of Blood Diseases and Stem Cell Transplantation, Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

22. University Clinical Centre Medical University of Warsaw Warsaw Poland

23. Department of Haematology and Stem Cell Transplantation University College London Hospitals NHS Trust London UK

24. Hematology and Bone Marrow Transplantation Unit, Hematology Department Federico II University of Naples Naples Italy

25. Department of Hematology Maria Skłodowska‐Curie National Research Institute of Oncology Gliwice Poland

26. Department of Hematology Hospital Clínico Universitario Valencia Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27262

Reference6 articles.

1. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

2. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

3. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

4. Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients

5. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of allogeneic stem cell transplantation in myelofibrosis;memo - Magazine of European Medical Oncology;2024-08-12

2. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-08

3. Myelofibrosis and allogeneic transplantation: critical points and challenges;Frontiers in Oncology;2024-06-20

4. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation;American Journal of Hematology;2024-05-14